Introduction: The study aimed to analyze the influence of restaging transurethral resection of bladder tumor (reTURB) timing on outcomes in patients receiving Bacillus Calmette-Guerin (BCG) immunotherapy. Material and Methods: This retrospective study enrolled 491 patients with bladder cancer receiving BCG intravesical therapy between 1998 and 2016. All patients were followed up for at least 12 months and received at least 7 BCG instillations. The patients were analyzed in terms of recurrence free, progression free, and cancer specific survival (CSS). Results: Median follow-up was 57 months (12–257 months). The risk for all analyzed clinical events was higher in patients who underwent reTURB after 6 weeks from primary TURB. After the change point of 57 days after primary resection, further delay was not associated with increased risk of recurrence and progression. The time limit for CSS was 76 days. With every 1 more day of time interval between TURB and reTURB, the risk of each clinical event in follow-up increased by 4%. Conclusions: There is no benefit of the reTURB performed after 8 weeks from primary TURB. Optimal timing of reTURB is from 2 to 6 weeks after initial TURB. However, even within this time frame, the sooner the procedure is performed, the risk of recurrence, progression, or cancer-specific death is lower.

Keywords:
Bladder cancer, Transurethral resection, Bacillus Calmette-Guerin, Recurrence, Progression
1.
Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R: EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447–461.
2.
Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA: Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol 2007; 177: 867–875; discussion 875.
3.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M; European Association of Urology: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European urology 2013; 64: 639–653.
4.
Novotny V, Froehner M, Ollig J, Koch R, Zastrow S, Wirth MP: Impact of adjuvant intravesical bacillus calmette-guerin treatment on patients with high-grade T1 bladder cancer. Urol Int 2016; 96: 136–141.
5.
Sooriakumaran P, Chiocchia V, Dutton S, Pai A, Ayres BE, Le Roux P, Swinn M, Bailey M, Perry MJ, Issa R: Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients. Urol Int 2016; 96: 83–90.
6.
Poletajew S, Zapala P, Radziszewski P: Safety and efficacy of intravesical bacillus calmette-guerin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review. Urol Int 2017; 99: 1–5.
7.
Bishr M, Lattouf JB, Latour M, Saad F: Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J 2014; 8:E306–E310.
8.
Kim W, Song C, Park S, Kim J, Park J, Kim SC, Cho YM, Hong B, Ahn H: Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol 2012; 26: 1059–1064.
9.
Dobruch J, Borowka A, Herr HW: Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 2014; 84: 881–885.
10.
Babjuk M: Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives. Eur Urol 2010; 58: 191–192.
11.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124–1129.
12.
Singer J, Willett J: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, Oxford University Press, 2003.
13.
Muggeo VM: Estimating regression models with unknown break-points. Stat Med 2003; 22: 3055–3071.
14.
Team RC: A Language and Environment for Statistical Computing. Vienna, 2017.
15.
Baltaci S, Bozlu M, Yildirim A, Gokce MI, Tinay I, Aslan G, Can C, Turkeri L, Kuyumcuoglu U, Mungan A: Significance of the -interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin. BJU Int 2015; 116: 721–726.
16.
Balci M, Tuncel A, Keten T, Guzel O, Lokman U, Koseoglu E, Aslan Y, Atan A: Comparison of monopolar and bipolar transurethral resection of non-muscle invasive bladder cancer. Urol Int 2018; 100: 100–104.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.